Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo + semaglutide
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This is a combination of placebo and semaglutide. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes, obesity, and to reduce the risk of major cardiovascular events and chronic kidney disease in certain adult patients. It works by mimicking endogenous GLP-1, stimulating insulin secretion, suppressing glucagon release in a glucose-dependent manner, reducing appetite, delaying gastric emptying, and promoting weight loss[1][5][7]. Placebo is an inactive substance with no therapeutic effect used as a control in clinical trials.
02
Targets
Beyond the preview
Go deeper on placebo + semaglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placebo + semaglutide.